Interactions with antiinfective agents. Adverse drug reactions in multidrug therapy;Interaktionen mit antiinfektiva: Unerwünschte arzneimittelwirkungen bei der einnahme mehrerer medikamente

PZ Prisma

Volumn 9, Issue 4, 2002, Pages 217-228

  Siegmund, Werner ^a   Weitschies, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; CERIVASTATIN; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; CYCLOSPORIN; DOXYCYCLINE; ENOXACIN; ERYTHROMYCIN; FLUCONAZOLE; GREPAFLOXACIN; ITRACONAZOLE; KETOCONAZOLE; LEVOFLOXACIN; MACROLIDE; MIBEFRADIL; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PHENPROCOUMON; PROTEINASE INHIBITOR; QUINOLONE DERIVATIVE; ROXITHROMYCIN; SPARFLOXACIN; TACROLIMUS; TERFENADINE; THEOPHYLLINE; UNINDEXED DRUG;

BIOTRANSFORMATION; DRUG ABSORPTION; DRUG ELIMINATION; DRUG SCREENING; PHARMACODYNAMICS; REVIEW;

EID: 0036428935     PISSN: 09455566     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Schönhöfer, P. S.; Wille, H.; Lelgemann, M.; Werner, B.; von Maxen, A.; Vagt, A.: Unerwünschte arzneimittelwirkungen. Pathophysiologie, häufigkeit, erfassung und bedeutung für die risikoabwehr. DGPT-Forum 28, 15-19 (2001)
2. Goettler, M.; Schneeweiss, S.; Hasford: Adverse drug reaction monitoring - Cost and benefit consideration part II: Cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Safety 6 Suppl. 3, 79-90 (1997)
3. Lazarou, J.; Pomeranz, B. H.; Corey, P. N.: Incidence of adverse drug reactions in hospitalized patients. J Am Med Assoc 279, 1200-1205 (1998)
4. Cardiovascular News: Withdrawal of posicor from market. Circulation 98, 831-832 (1998)
5. Mullins, M. E.; Horowitz, B. Z.; Linden, D. H.; Smith, G. W.; Norton, R. L.; Stump, J.: Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. J Am Med Assoc 280, 157-158 (1998)
6. Köhler, G. I.; Bode-Böger, S. M.; Busse, R.; Hoopmann, M.; Welte, T.; Böger, R. H.: Drug-drug interactions in elderly patients. Relation to hospital admissions and multiple drug use. Int J Clin Pharmacol Ther 38, 504-513 (2000)
7. Schröder, H.; Selke, G. W.: Arzneimittelverordnungen nach alter und geschlecht. In: Schwabe U, Paffrath (Hrsg.): Arzneiverordnungsreport 1999. Berlin, Heidelberg, 2000, S. 684-696
8. Borda, I. T.; Slone, D.; Mick, H.: Assessment of adverse reactions within a drug surveillance program. J Am Med Assoc 205,645-647 (1968)
9. Levy, M.; Kewitz, H.; Altwein, W.; Hildebrand, J.; Eliakim, M.: Hospital admissions due to adverse drug reactions: A comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol 17, 25-31 (1980)
10. Popplewell, P. Y.; Henschke, P. J.: Acute admission to a geriatric assessment unit. Med J Aust 1, 343-344 (1982)
11. Williamson, J.; Chopin, J. M.: Adverse reactions to prescribed drugs in the elderly: A multicenter investigation. Age Ageing 9, 73-80 (1980)
12. Joshi, N.; Miller, D. Q.: Doxycycline revisited. Arch Intern Med 157, 1421-1428 (1997)
13. De Sarro, A.; De Sarro, G.: Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem 8, 371-384 (2001)
14. Deppermann, K. M.; Lode, H.: Fluoroquinolones: Interaction profile during enteral absorption. Drugs 45 Suppl 3, 65-72 (1993)
15. Pai, M. P.; Graci, D. M.; Amsden, G. W.: Macrolide drug interactions: An update. Ann Pharmacother 34, 495-513 (2000)
16. Westphal, J. F.: Macrolide - Induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50, 285-295 (2000)
17. Kitaichi, K.; Wang, L.; Takagi, K.; Iwase, M.; Shibata, E.; Nadai, M.; Hasegawa, T.: Decreased antipyrine clearance following endotoxin administration: In vivo evidence of the role of nitric oxide. Antimicrob Agents Chemother 43, 2697-2701 (1999)
18. Sonne, J.; Dossing, M.; Loft, S.; Andreassen, P. B.: Antipyrine clearance in pneumonia. Clin Pharmacol Ther 37, 701-703 (1985)
19. Williams, S. J.; Baird-Lambert, J. A.; Farrell, G. C.: Inhibition of theophyllin metabolism by interferon. Lancet ii, 939-941 (1987)
20. Laberge, P.; Martineau, P.: Clarithromycin-induced digoxin intoxication. Ann Pharmacother 31, 999-1002 (1997)
21. Hofsli, E.; Nissen-Meyer, J.: Reversal of drug resistance by erythromycin: Erythromycin increases the accumulation of actinomycin D and doxorubicin in multi-drug resistant cells. Int J Cancer 44, 149-154 (1989)
22. Wakasugi, H.; Yano, I.; Ito, T.; Hashida, T.; Futami, T.; Nohara, R.; Sasayama, S.; Inui K.: Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein. Clin Pharmacol Ther 64, 123-128 (1998)
23. Clark, D. W.: Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29, 342-375 (1985)
24. Walubo, A.; Aboo, A.: Phenytoin toxicity due to concomitant antituberculosis therapy. Afr Med J 85, 1175-1176
25. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H. P.; Brockmüller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U.: Functional polymorphism of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 97, 3473-3478 (2000)
26. Albengres, E.; Le Louet, H.; Tillement, J. P.: Systemic antifungal agents. Drug interactions of clinical significance. Drug Safety 18, 83-97 (1998)
27. Lomaesstro, B. M.; Piatek, M. A.: Update on drug interactions with azole antifungal agents. Ann Pharmacother 32, 915-928 (1998)
28. Jetter, A.; Fuhr, U.: Medikamenteninteraktionen mit Chinolonen. Pharm Unserer Zeit 30, 429-434 (2001)
29. Hurst, M.; Faulds, D.: Lopinavir. Drugs 60, 1371-1379 (2000)
30. Self, T. H.; Chrisman, C. R.; Baciewicz, A. M.; Bronze, M. S.: Isoniazid drug and food interactions. Am J Med Sci 317, 304-311 (1999)
31. Strayhorn, V. A.; Baciewicz, A. M.; Self, T. H.: Update on rifampin drug interactions, III. Arch Intern Med 157, 2453-2458 (1997)
32. Böger, R. H.: Drug interactions of the statins and consequences for drug selection. Int J Clin Pharmacol Ther 39, 369-382 (2001)
33. Boberg, M.; Angerbauer, R.; Fey, P.; Kanhai, W. K.; Karl, W.; Kern, A.; Ploschke, J.; Radtke, M.: Metabolism of cerivastatin by human liver microsomes in vitro: characterization of primary metabolic pathways and of cytochrome P450 isoenzymes involved. Drug Metab Dispos 25, 321-331 (1997)
34. Arnadottir, M.; Eriksson, L.O.; Thysell, H.; Krakas, J. D.: Plasma concentration profiles of simvastatin. Nephron 65, 410-413 (1993)
35. Olbricht, C.; Wanner, C.; Eisenhauer, T.; Kliem, V.; Doll, R.; Boddaert, M.; O'Grady, P.; Krekler, M.; Marigold, B.; Christians, U.: Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62, 311-321 (1997)
36. Mück, W.; Mai, I.; Fritsche, L.; Ochmann, K.; Rohde, G.; Unger, S.; Johne, A.; Bauer, S.; Budde, K.; Roots, I.; Neumayer, H. H.; Kuhlmann, J.: Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65, 251-261 (1999)
37. Backman, J. T.; Kyrklund, C.; Kivistö, K.; Wang, J. S.; Neuvonen, P. J.: Plasma concentrations of active simvastatin acid are increased by gemfibrocil. Clin Pharmacol Ther 68, 122-129 (2000)
38. Kyrklund, C.; Backman, J. T.; Kivistö, K. T.; Neuvonen, M.; Laitila, J.; Neuvonen, P. J.: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69, 340-345 (2001)
39. Juliano, R. L.; Ling; V:: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455, 152-162 (1976)
40. Juranka, P. F.; Zastawny, R. L.; Ling, V.: P-glycoprotein: Multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3, 2583-2592 (1989)
41. Schinkel, A.: The physiological function of drug-transporting P-glycoproteins. Sem Cancer Biol 8, 161-170 (1997)
42. Cascorbi, I.; Gerloff, T.; Johne, A.; Meisel, C.; Hoffmeyer, S.; Schwab, M. et al.: Frequency of single nuceotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69, 169-174 (2001)
43. Cordon-Cardo, C.; O'Brien, J. P.; Boccia, J.; Casals, D.; Bertino, J. R.; Melamed, M. R.: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38, 1277-1287 (1990)
44. Fricker, G.; Drewe, J.; Huwyler, J.; Gutmann, H.; Beglinger, C.: Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro - In vivo correlation. Br J Pharmacol 118, 1841-1847 (1996)
45. Hunter, J.; Hirst, B. H.: Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 25, 129-157 (1997)
46. Silverman, J. A.: Multidrug-resistance transporters. In: Amidon and Sadée (ed): Membrane Transporters as Drug Targets. Kluwer Acedemic/Plenum Publisher, New York, 1999, S. 353-386
47. Sugawara, I.; Katoaka, I.; Morishita, Y.; Hamada, H.; Tsuruo, T.; Itoyama, S.; Mori, S.: Tissue distribution of p-glycoprotein encoded by a multidrug-resistance gene as revealed by a monoclonal antibody, MRK16. Cancer Res 48, 1926-1929 (1988)
48. Suzuki, H.; Sugiyama, Y.: Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12, 3-12 (2000)
49. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I.; Willingham, M. C.: Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues. Proc Natl Acad Sci 84, 7735-7738 (1987)
50. Zhang, Y.; Benet, L. Z.: The gut as a barrier to drug absorption. Combined role of cytochrome P4503A and P-glycoprotein. Clin Pharmacokinet 40, 159-168 (2001)
51. Lown, K. S.; Mayo, R. R.; Leichtman, A. B.; Hsiao, H.; Turgeon, K.; Schmiedlin-Ren, P.; Brown, M. B.; Guo, W.; Rossi, S.J.; Benet, L. Z.; Watkins, P. B.: Role of intestinal P- glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62, 248-260 (1997)
52. Farrell, R. J.; Murphy, A.; Long, A.; Donnelly, S.; Cherikuri, A.; O'Toole, D. et al.: High multidrug resistance (P-glycoprotein 170) expession in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118, 279-288 (2000)
53. Hitzl, M.; Drescher, S.; van der Kuip, H.; Schäffeler, E.; Fischer, J.; Schwab, M. et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P- glycoprotein substrate rhodamine 123 CD56+ natural killer cells. Pharmacogenetics 11, 293-298 (2001)
54. Kim, R. B.; Leake, B. F.; Choo, E. F.; Dresser, G. K.; Kubba, S. V.; Schwarz, U. I. et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70, 189-199 (2001)
55. Tanabe, M.; Ieiri, I.; Nagata, N.; Inoue, K.; Ito, S.; Kanamori, Y. et al.: Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297, 1137-1143 (2001)
56. Tisher, D. M.; Weinberg, K. I.; Hinton, D. R.; Barbaro, N.; Annett, G. M.; Raffel, C.: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36, 1-6 (1995)
57. Desmond Padhi, I. D.; Long, P.; Basha, M.; Anandan, I. V.: Interaction between tacrolimus and erythromycin. Ther Drug Monitor 19, 120-121 (1997)
58. Hebert, M. F.; Fisher, R. M.; Marsh, C. L.; Dressler, D.; Bekersky, I.: Effects of rifampin on tracrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39, 91-96 (1999)
59. Calvo, M. V.; Martin-Suarez, A.; Martin-Luengo, C.; Avila, C.; Cascon, M.; Dominguez-Gil, H. A.: Interaction between digoxin and propafenone. Therap Drug Monit 11, 10-15 (1989)
60. Fenster, P. E.; White, N. W.; Hanson, C. D.: Pharmacokinetic evaluation of the digoxin-amiodarone interaction. J Am Coll Cardiol 5, 108-112 (1985)
61. Fromm, M. F.; Kim, R. B.; Stein, C. M.; Wilkinson, G. R.; Roden, D. M.: Inhibition of P-glycoprotein mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99, 552-557 (1999)
62. Hager, W. D.; Fenster, P.; Mayersohn, M.; Perrier, D.; Graves, P.; Marcus, F. I. et al.: Digoxin-quinidine interaction: Pharmacokinetic evaluation. N Engl J Med 300, 1238-1241 (1979)
63. Jalava, K. M.; Partanen, J.; Neuvonen, P. J.: Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19, 609-613 (1997)
64. Pedersen, K. E.; Dorph-Pedersen, A.; Hvidt, S.; Klitgaard, N. A.; Nielsen-Kudsk, F.: Digoxin-verapamil interaction. Clin Pharmacol Ther 30, 311-316 (1981)
65. Robieux, I.; Dorian, P.; Klein, J.; Chung, D.; Zborowska-Sluis, D.; Ogilvie, R. et al.: The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. J Clin Pharmacol 32, 338-343 (1992)
66. Westphal, K.; Weinbrenner, A.; Gießmann, T.; Stuhr, M.; Franke, G.; Zschiesche, M.; Oertel, R.; Terhaag, B.; Kroemer, H. K.; Siegmund, W.: Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68, 6-12 (2000)
67. Dürr, D.; Stieger, B.; Kullak-Ublick, G. A.; Rentsch, K. M.; Steinert, H. C.; Meier, P. J.; Fattinger, K.: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68, 598-604 (2000)
68. Geick, A.; Eichelbaum, M.; Burk, O.: Nuclear response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276, 14581-14587 (2001)
69. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H. P.; von Richter, O.; Zundler, J. and Kroemer, H. K.: The interaction of digoxin and rifampin: Role of intestinal P-glycoprotein. J Clin Invest; 104, 147-153 (1999)
70. Johne, A.; Brockmöller, J.; Bauer, S.; Maurer, A.; Langheinrich, M.; Roots, I.: Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 66, 338-345 (1999)
71. Altmannsberger, S.; Paneitz, A.; Franke, G.; Knoke, M.; Sperker, B.; Terhaag, B.; Meng, W.; Warzok, R.; Schroeder, E.; Weibrenner, A.; Zschiesche, M.; Cascorbi, I.; Kroemer, H. K.; Siegmund, W: Chronic thyroxine induces intestinal P-glycoprotein and elimination of talinolol in healthy volunteers. Eur J Clin Pharmacol 56 Suppl. A, 16 (2000)
72. Schwarz, U. I.; Gramatté, T.; Krappweis, J.; Oertel, R.; Kirch, W.: P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38, 161-167 (2000)
73. Westphal, K.; Weinbrenner, A.; Zschiesche, M.; Franke, G.; Knoke, M.; Oertel, R.; Fritz, P.; von Richter, O.; Warzok, R.; Hachenberg, T.; Kaufmann, H. M.; Schrenk, D.; Terhaag, B.; Kroemer, H. K.; Siegmund, W.: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in humn beings: A new type of drug/drug interaction. Clin Pharmacol Ther 68, 345-355 (2000)
74. Ucar, M.; Dahlqvist, R.: HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 22, 441-457 (2000)
75. Bertz, R. J.; Granneman, G. R.: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32, 210-258 (1997)
76. Guengerich, F. P.: Human cytochrome P450 enzymes. In: Ortiz de la Nontellano PR (ed): Cytochrome P450: Structure, Mechanism, and Biochemistry. 2nd Ed. Plenum, New York, 1995, S. 473-535